AGP Picks
View all

Cholangiocarcinoma market seen reaching $1.14 billion by 2030

4 hours ago
Cholangiocarcinoma market seen reaching $1.14 billion by 2030
By AI, Created 19:30 UTC, Nov 18, 2026, AGP -

The cholangiocarcinoma market is projected to grow from $0.71 billion in 2026 to $1.14 billion by 2030, according to a new report from The Business Research Company. The forecast reflects rising liver disease rates, more oncology research, and greater use of targeted and personalized treatments.

Why it matters: - The cholangiocarcinoma market is expanding as more patients are diagnosed with bile duct cancer and demand grows for treatments beyond limited curative options. - The report points to a fast-growing niche in oncology that is being shaped by drug development, early detection efforts, and higher investment in rare-cancer research. - Liver disease trends matter because chronic liver inflammation and cirrhosis raise the risk of cholangiocarcinoma.

What happened: - The Business Research Company released its Cholangiocarcinoma Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The market is expected to rise from $0.62 billion in 2025 to $0.71 billion in 2026. - The report projects the market will reach $1.14 billion by 2030, at a CAGR of 12.8%. - North America held the largest share of the cholangiocarcinoma market in 2025. - The report also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

The details: - Historical growth has been driven by rising bile duct cancer cases, a shortage of curative treatment options, widespread chemotherapy use, more oncology centers, and an increasing number of drugs entering the oncology pipeline. - Future growth is expected to come from targeted oncology drug development, broader use of personalized medicine, more clinical trials for rare cancers, higher oncology research spending, and more emphasis on early diagnosis. - Key trends include targeted therapies, combination chemotherapy protocols, precision oncology, immunotherapy research, and better early detection methods. - Cholangiocarcinoma is a malignant tumor that begins in the bile ducts and can block bile flow and impair liver function. - Common symptoms include jaundice, abdominal discomfort, unintentional weight loss and fatigue. - Liver diseases linked to the market outlook include hepatitis, cirrhosis, fatty liver disease and liver cancer. - Risk factors for liver disease include obesity, diabetes, excessive alcohol consumption and viral hepatitis infections. - The UK's Office for Health Improvement and Disparities reported in December 2024 that premature deaths from alcoholic liver disease rose 3.6% in 2023 to 5,984 from 5,776 in 2022.

Between the lines: - The market's growth reflects a larger shift in oncology toward more precise treatment approaches for hard-to-treat cancers. - The report suggests that liver disease trends are not just a public health issue; they also expand the potential patient pool for cholangiocarcinoma therapies. - The emphasis on early detection signals that diagnosis may be becoming as important as treatment in this market.

What's next: - The market is likely to keep moving toward targeted therapies and combination regimens as research advances. - More clinical trials and oncology investment could widen the pipeline of treatments over the next several years. - Improved screening and earlier diagnosis may influence both patient outcomes and commercial opportunities. - The report includes new 2026 features such as market attractiveness scoring, TAM analysis, company scoring matrices, Excel dashboards and hotspot infographics. - More information is available in the full report and a free sample.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Middle East Business Channel

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Middle East Business Channel

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.